A 3-Armed Prospective Randomized Controlled, Open-Labeled Phase II Trial to Evaluate Late Introduction of Cyclosporine or Everolimus Versus a 5-day Delay of Cyclosporine in Combination With MMF in Liver Transplant Recipients With MELD-Scores greater than or equal to 25.

Trial Profile

A 3-Armed Prospective Randomized Controlled, Open-Labeled Phase II Trial to Evaluate Late Introduction of Cyclosporine or Everolimus Versus a 5-day Delay of Cyclosporine in Combination With MMF in Liver Transplant Recipients With MELD-Scores greater than or equal to 25.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Ciclosporin (Primary) ; Everolimus (Primary) ; Basiliximab; Corticosteroids; Mycophenolate mofetil; Mycophenolate mofetil
  • Indications Liver transplant rejection
  • Focus Adverse reactions; Registrational
  • Acronyms BUILT01
  • Most Recent Events

    • 04 Jul 2015 Status changed from recruiting to completed, as reported by European Clinical Trials Database record.
    • 02 Jul 2012 New source identified and integrated (European Clinical Trials Database: EudraCT2009-017192-26).
    • 30 Jun 2011 Trial phase changed from III to II/III as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top